Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910102 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2 study, sponsored by Axovant Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT02910102 is a Phase 2 study that has completed, run by Axovant Sciences. The registered enrollment target is 38 participants.
The verdict
NCT02910102, a Phase 2 study, has completed, sponsored by Axovant Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.
Interventions
- DRUG Placebo
- DRUG RVT-101 35 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-10 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02910102
The ClinicalTrials.gov registry entry for NCT02910102 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axovant Sciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02910102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02910102 about?
NCT02910102 is a clinical study titled "Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia". This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.
What is the current status of trial NCT02910102?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2016-10. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02910102?
The interventions under investigation include: Placebo (DRUG), RVT-101 35 mg (DRUG).
Who is sponsoring clinical trial NCT02910102?
This trial is sponsored by Axovant Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.